Show All
At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit GeneDx.com.
GeneDx’s headquarters are located in Stamford, Connecticut.
GeneDx is listed on the Nasdaq stock exchange under the ticker "WGS". Public warrants will trade under the ticker symbol WGSWW.
GeneDx began trading under WGS on January 10, 2023. The Company previously traded under SMFR, reflective of the company’s former name, Sema4 which went public via merger with CM Life Sciences (CMLF), a special purpose acquisition company (SPAC), on July 23, 2021.
GeneDx’s fiscal year end is December 31.
We have never paid any cash dividends on our capital stock. We anticipate that we will retain earnings, if any, to support operations and to finance the growth and development of our business. In addition, the terms of the revolving credit facility with Silicon Valley Bank, or SVB, precludes us from paying cash dividends without the prior written consent of SVB. Therefore, we do not expect to pay cash dividends for the foreseeable future.
GeneDx does not currently have a direct stock purchase plan.
SEC filings can be found here or directly from the SEC at www.sec.gov.
GeneDx’s independent registered public accountants are Ernst & Young LLP.
Fenwick & West LLP serves as our external legal counsel and can be reached at:
Ethan Skerry
Per B. Chilstrom
Fenwick & West LLP
902 Broadway New York, New York 10010
(212) 430-2600
Our transfer agent is Continental Stock Transfer & Trust Company and can be reached at:
Website: https://continentalstock.com
Email: cstmail@continentalstock.com
Telephone: 212.509.4000
Mail: 1 State Street, 30th Floor | New York, NY 10004-1561
Website: https://continentalstock.com
Email: cstmail@continentalstock.com
Telephone: 212.509.4000
Mail: 1 State Street, 30th Floor | New York, NY 10004-1561
You can view our Board of Directors by visiting the Board of Directors section of our website here.
You can view our management team by visiting the Management Team section of our website here.
You can contact GeneDx Investor Relations via email at investors@genedx.com .